SG11201408076WA - Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide - Google Patents
Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamideInfo
- Publication number
- SG11201408076WA SG11201408076WA SG11201408076WA SG11201408076WA SG11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA SG 11201408076W A SG11201408076W A SG 11201408076WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ylmethylamino
- quinazolin
- sulfonamide
- pyridin
- Prior art date
Links
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 title abstract 2
- 229940061584 phosphoramidic acid Drugs 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- XGKULQQVQWCASY-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 XGKULQQVQWCASY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000006870 function Effects 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- -1 PYRIDIN- 2 - YLMETHYLAMINO Chemical class 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188254 A1 (51) International Patent Classification: C07D 401/14 (2006.01) C07F 9/6558 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044882 10 June 2013 (10.06.2013) English English (30) Priority Data: 61/657,913 11 June 2012 (11.06.2012) (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: WARRIER, Jayakumar S.; Biocon Park Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099 (IN). YADEV, Navnath Dnyanoba; Biocon Park Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099 (IN). (74) Agents: VANATTEN, Mary K. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US). Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: PHOSPHORAMIDIC ACID PRODRUGS OF QUINAZOLIN- 2 - YL] PYRIDINE- 3 - SULFONAMIDE [5 - PHENYL- 4 - (PYRIDIN- 2 - YLMETHYLAMINO) (I) CJ oo 00 T-H O (57) Abstract: A compound of structural formula (I), wherein R is H or -P03H or a pharmaceutically acceptable salt form thereof. ^ The compounds are useful as inhibitors of channel function potassium and in the treatment and prevention of arrhythmia, I ur-associ- K Q ated disorders, and other disorders mediated by ion channel function.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657913P | 2012-06-11 | 2012-06-11 | |
| PCT/US2013/044882 WO2013188254A1 (en) | 2012-06-11 | 2013-06-10 | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408076WA true SG11201408076WA (en) | 2015-01-29 |
Family
ID=48670111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408076WA SG11201408076WA (en) | 2012-06-11 | 2013-06-10 | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9238666B2 (en) |
| EP (1) | EP2858987B1 (en) |
| JP (1) | JP6234450B2 (en) |
| KR (1) | KR102092984B1 (en) |
| CN (1) | CN104350048B (en) |
| AR (1) | AR091402A1 (en) |
| AU (1) | AU2013274619B2 (en) |
| BR (1) | BR112014030629B1 (en) |
| CA (1) | CA2876359C (en) |
| CL (1) | CL2014003361A1 (en) |
| CO (1) | CO7160032A2 (en) |
| CY (1) | CY1120432T1 (en) |
| DK (1) | DK2858987T3 (en) |
| EA (1) | EA024692B1 (en) |
| ES (1) | ES2675314T3 (en) |
| HK (1) | HK1203928A1 (en) |
| HR (1) | HRP20180815T8 (en) |
| HU (1) | HUE039210T2 (en) |
| IL (1) | IL236074A (en) |
| LT (1) | LT2858987T (en) |
| MX (1) | MX356699B (en) |
| MY (1) | MY169219A (en) |
| NZ (1) | NZ703632A (en) |
| PE (1) | PE20150228A1 (en) |
| PH (1) | PH12014502747B1 (en) |
| PL (1) | PL2858987T3 (en) |
| PT (1) | PT2858987T (en) |
| RS (1) | RS57376B1 (en) |
| SG (1) | SG11201408076WA (en) |
| SI (1) | SI2858987T1 (en) |
| TN (1) | TN2014000499A1 (en) |
| TW (1) | TWI571470B (en) |
| WO (1) | WO2013188254A1 (en) |
| ZA (1) | ZA201500161B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| JP6386527B2 (en) * | 2013-03-11 | 2018-09-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Pyrrolopyridazine as a potassium ion channel inhibitor |
| JP6395798B2 (en) * | 2013-03-11 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Pyrrolotriazines as potassium ion channel inhibitors |
| JP7110094B2 (en) * | 2015-11-19 | 2022-08-01 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | Amine Prodrugs of Pharmaceutical Compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| KR20010083092A (en) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists |
| ES2215474B1 (en) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | NEW DERIVATIVES OF PHOSPHORAMIDE. |
| AR049847A1 (en) | 2004-07-29 | 2006-09-06 | Merck & Co Inc | POTASSIUM CHANNEL INHIBITORS |
| WO2006066879A2 (en) * | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| DK2473487T3 (en) | 2009-09-03 | 2017-02-06 | Bristol Myers Squibb Co | QUINAZOLINES AS CALCIUM CHANNEL INHIBITORS |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AR079814A1 (en) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES |
| ES2691671T3 (en) * | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014143609A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
-
2013
- 2013-06-10 WO PCT/US2013/044882 patent/WO2013188254A1/en active Application Filing
- 2013-06-10 EA EA201492256A patent/EA024692B1/en not_active IP Right Cessation
- 2013-06-10 PE PE2014002405A patent/PE20150228A1/en active IP Right Grant
- 2013-06-10 JP JP2015517321A patent/JP6234450B2/en active Active
- 2013-06-10 CN CN201380030478.2A patent/CN104350048B/en active Active
- 2013-06-10 BR BR112014030629-0A patent/BR112014030629B1/en active IP Right Grant
- 2013-06-10 KR KR1020157000330A patent/KR102092984B1/en active IP Right Grant
- 2013-06-10 TW TW102120593A patent/TWI571470B/en active
- 2013-06-10 MX MX2014014525A patent/MX356699B/en active IP Right Grant
- 2013-06-10 HU HUE13730444A patent/HUE039210T2/en unknown
- 2013-06-10 EP EP13730444.0A patent/EP2858987B1/en active Active
- 2013-06-10 AR ARP130102043 patent/AR091402A1/en not_active Application Discontinuation
- 2013-06-10 SG SG11201408076WA patent/SG11201408076WA/en unknown
- 2013-06-10 LT LTEP13730444.0T patent/LT2858987T/en unknown
- 2013-06-10 CA CA2876359A patent/CA2876359C/en active Active
- 2013-06-10 PT PT137304440T patent/PT2858987T/en unknown
- 2013-06-10 SI SI201331033T patent/SI2858987T1/en unknown
- 2013-06-10 DK DK13730444.0T patent/DK2858987T3/en active
- 2013-06-10 NZ NZ703632A patent/NZ703632A/en unknown
- 2013-06-10 RS RS20180738A patent/RS57376B1/en unknown
- 2013-06-10 US US14/406,543 patent/US9238666B2/en active Active
- 2013-06-10 PL PL13730444T patent/PL2858987T3/en unknown
- 2013-06-10 ES ES13730444.0T patent/ES2675314T3/en active Active
- 2013-06-10 AU AU2013274619A patent/AU2013274619B2/en active Active
- 2013-06-10 MY MYPI2014703715A patent/MY169219A/en unknown
-
2014
- 2014-11-28 TN TN2014000499A patent/TN2014000499A1/en unknown
- 2014-12-04 IL IL236074A patent/IL236074A/en active IP Right Grant
- 2014-12-09 PH PH12014502747A patent/PH12014502747B1/en unknown
- 2014-12-10 CL CL2014003361A patent/CL2014003361A1/en unknown
-
2015
- 2015-01-08 CO CO15003999A patent/CO7160032A2/en unknown
- 2015-01-09 ZA ZA2015/00161A patent/ZA201500161B/en unknown
- 2015-05-06 HK HK15104313.5A patent/HK1203928A1/en unknown
-
2018
- 2018-05-24 HR HRP20180815TT patent/HRP20180815T8/en unknown
- 2018-07-13 CY CY20181100733T patent/CY1120432T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
| SG11201408160TA (en) | Phosphinyl guanidine compounds, metal salt complexes, catalyst systems, and their use to oligomerize or polymerize olefins | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds |